$TARA News

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

What Makes Protara Therapeutics (TARA) a New Buy Stock

Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations - Slideshow

Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

Protara Therapeutics To Host Investor Webinar On TARA-002 Program And Treatment Landscape For Lymphatic Malformations On May 19, 2026

Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

Protara Therapeutics Reports TARA-002 Achieves 72% Complete Response Rate In BCG-Naïve NMIBC Patients With Durable 55% Rate At 12 Months

JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics Q1 EPS $(0.31) Beats $(0.37) Estimate

One Protara Therapeutics Insider Raised Their Stake In The Previous Year